Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Louis M Havekes

Showing results (1-10 of 167) with videos related to

Pageof 17
Sort By:
Arteriosclerosis, Thrombosis, and Vascular Biology|March 25, 2006
Cholesteryl ester transfer protein inhibition: effect on reverse cholesterol transport?Patrick C N Rensen, Louis M Havekes
Journal of Endotoxin Research|June 14, 2005
Apolipoproteins modulate the inflammatory response to lipopolysaccharideJimmy F P Berbée, Louis M Havekes, Patrick C N Rensen
Current Opinion in Clinical Nutrition and Metabolic Care|June 11, 2008
Gut-brain axisJohannes A Romijn, Eleonora P Corssmit, Louis M Havekes, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|November 25, 2005
Apolipoprotein AV: low concentration, high impactPatrick C N Rensen, Ko Willems van Dijk, Louis M Havekes
The Journal of Biological Chemistry|December 4, 2004
Generation of a recombinant apolipoprotein E variant with improved biological functions: hydrophobic residues (LEU-261, TRP-264, PHE-265, LEU-268, VAL-269) of apoE can account for the apoE-induced hypertriglyceridemiaKyriakos E Kypreos, Ko W van Dijk, Louis M Havekes, et al.
Blood|April 21, 2005
LDL receptor cooperates with LDL receptor-related protein in regulating plasma levels of coagulation factor VIII in vivoNiels Bovenschen, Koen Mertens, Lihui Hu, et al.
Current Opinion in Lipidology|May 29, 2004
The role and mode of action of apolipoproteins CIII and AV: synergistic actors in triglyceride metabolism?Ko Willems van Dijk, Patrick C N Rensen, Peter J Voshol, et al.
Atherosclerosis|March 23, 2013
Interactions between inflammation and lipid metabolism: relevance for efficacy of anti-inflammatory drugs in the treatment of atherosclerosisJanna A van Diepen, Jimmy F P Berbée, Louis M Havekes, et al.
Plos One|March 6, 2013
Acute central neuropeptide Y administration increases food intake but does not affect hepatic very low-density lipoprotein (VLDL) production in miceJanine J Geerling, Yanan Wang, Louis M Havekes, et al.
Biochemistry|August 20, 2003
Molecular mechanisms of type III hyperlipoproteinemia: The contribution of the carboxy-terminal domain of ApoE can account for the dyslipidemia that is associated with the E2/E2 phenotypeKyriakos E Kypreos, Xiaoping Li, Ko Willems van Dijk, et al.
Pageof 17

Showing results (1-10 of 167) with videos related to

Sort By:
Pageof 17
Arteriosclerosis, Thrombosis, and Vascular Biology|March 25, 2006
Cholesteryl ester transfer protein inhibition: effect on reverse cholesterol transport?Patrick C N Rensen, Louis M Havekes
Journal of Endotoxin Research|June 14, 2005
Apolipoproteins modulate the inflammatory response to lipopolysaccharideJimmy F P Berbée, Louis M Havekes, Patrick C N Rensen
Current Opinion in Clinical Nutrition and Metabolic Care|June 11, 2008
Gut-brain axisJohannes A Romijn, Eleonora P Corssmit, Louis M Havekes, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|November 25, 2005
Apolipoprotein AV: low concentration, high impactPatrick C N Rensen, Ko Willems van Dijk, Louis M Havekes
The Journal of Biological Chemistry|December 4, 2004
Generation of a recombinant apolipoprotein E variant with improved biological functions: hydrophobic residues (LEU-261, TRP-264, PHE-265, LEU-268, VAL-269) of apoE can account for the apoE-induced hypertriglyceridemiaKyriakos E Kypreos, Ko W van Dijk, Louis M Havekes, et al.
Blood|April 21, 2005
LDL receptor cooperates with LDL receptor-related protein in regulating plasma levels of coagulation factor VIII in vivoNiels Bovenschen, Koen Mertens, Lihui Hu, et al.
Current Opinion in Lipidology|May 29, 2004
The role and mode of action of apolipoproteins CIII and AV: synergistic actors in triglyceride metabolism?Ko Willems van Dijk, Patrick C N Rensen, Peter J Voshol, et al.
Atherosclerosis|March 23, 2013
Interactions between inflammation and lipid metabolism: relevance for efficacy of anti-inflammatory drugs in the treatment of atherosclerosisJanna A van Diepen, Jimmy F P Berbée, Louis M Havekes, et al.
Plos One|March 6, 2013
Acute central neuropeptide Y administration increases food intake but does not affect hepatic very low-density lipoprotein (VLDL) production in miceJanine J Geerling, Yanan Wang, Louis M Havekes, et al.
Biochemistry|August 20, 2003
Molecular mechanisms of type III hyperlipoproteinemia: The contribution of the carboxy-terminal domain of ApoE can account for the dyslipidemia that is associated with the E2/E2 phenotypeKyriakos E Kypreos, Xiaoping Li, Ko Willems van Dijk, et al.
Pageof 17